PhRMA Wades Into FDA Patient-Focused Data Collection: Website Systems for Crowd-Sourced Info
This article was originally published in RPM Report
Executive Summary
Trade association partners with Genetic Alliance to provide input into FDA drug development initiative. That may be an effective intervention by PhRMA as it experiments with new ways to shape regulatory policy beyond traditional advocacy efforts.
You may also be interested in...
Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
Getting a Jump on PDUFA V: Fast Start on REMS, Patient Input – And Longer Reviews
The new Prescription Drug User Fee Act Program doesn’t take effect until October 1, but FDA has been getting moving on some key elements of the program since before the final negotiations began on Capitol Hill. FDA will need to move fast to meet the many policy deadlines set by the agreement negotiated with industry.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.